Regeneron Pharmaceuticals Investor Presentation — December 2020

Document content

This presentation includes forward -looking statements thatinvolve risks anduncertainties relating tofuture events andthefuture performance ofRegeneron Pharmaceuticals, Inc.(“Regeneron” orthe“Company”), andactual

events orresults may differ materially from these forward -looking statements .Words such as“anticipate,” “expect,”“intend,”“plan,”“believe,”“seek,”“estimate,” variations ofsuch words, andsimilar expressions areintended

toidentify such forward -looking statements, although notallforward -looking statements contain these identifying words .These statements concern, andthese risks anduncertainties include, among others, theimpact of

SARS -CoV-2(the virus that has caused theCOVID -19pandemic) onRegeneron's business and itsemployees, collaborators, and suppliers and other third parties onwhich Regeneron relies, Regeneron's and its

collaborators’ ability tocontinue toconduct research andclinical programs, Regeneron's ability tomanage itssupply chain, netproduct sales ofproducts marketed orotherwise commercialized byRegeneron and/or its

collaborators (collectively, "Regeneron’s Products"), andtheglobal economy ;thenature, timing, andpossible success andtherapeutic applications ofRegeneron’s Products andRegeneron’s product candidates andresearch

and clinical programs now underway orplanned, including without limitation Libtayo ®(cemiplimab ),Regeneron’s and itscollaborators’ other oncology programs (including odronextamab (REGN 1979 ),REGN 5458 ,

REGN 4018 ,REGN 5678 ,REGN 5668 ,REGN 7075 ,REGN 5093 ,andREGN 6569 ),Regeneron’s anditscollaborators’ other hematology programs (including pozelimab (REGN 3918 )andREGN 7257 ),Regeneron’s andits

collaborators’ earlier -stage programs, andtheuseofhuman genetics inRegeneron’s research programs ;safety issues resulting from theadministration ofRegeneron’s Products andproduct candidates inpatients, including

serious complications orside effects inconnection with theuseofRegeneron’s Products andproduct candidates inclinical trials ;thelikelihood, timing, andscope ofpossible regulatory approval andcommercial launch of

Regeneron’s product candidates and new indications forRegeneron’s Products, including without limitation Libtayo ,Regeneron’s and itscollaborators’ other oncology programs (including odronextamab (REGN 1979 ),

REGN 5458 ,REGN 4018 ,REGN 5678 ,REGN 5668 ,REGN 7075 ,REGN 5093 ,andREGN 6569 ),andRegeneron’s anditscollaborators’ other hematology programs (including pozelimab (REGN 3918 )andREGN 7257 );the

possible success ofRegeneron’s oncology strategy and thelikelihood and timing ofachieving anyoftheanticipated milestones described inthispresentation ;theextent towhich theresults from theresearch and

development programs conducted byRegeneron and/or itscollaborators may bereplicated inother studies and/or lead toadvancement ofproduct candidates toclinical trials, therapeutic applications, orregulatory approval ;